# Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus

> **NCT03973515** · PHASE1 · COMPLETED · sponsor: **PegBio Co., Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Type2 Diabetes Mellitus

## Interventions

- **DRUG:** glucokinase activator
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03973515
- **Lead sponsor:** PegBio Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-27
- **Primary completion:** 2019-12-19
- **Final completion:** 2019-12-19
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03973515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03973515, "Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03973515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*